Matches in SemOpenAlex for { <https://semopenalex.org/work/W2364490023> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2364490023 abstract "Objective To evaluate the efficacy and safety of low molecular weight heparin (LMWH) compared with standard heparin (SH). Methods A prospective, multicenter, randomized clinical trial was conducted. Patients with at least one attack of ischemic chest pain caused by unstable angina or non Q wave myocardial infarction within 48 hours prior to the treatment were enrolled. They were randomized to one of the two treatment groups, i.e., group SH: heparin, 100 IU/kg i.v. as a bolus, followed by continuous infusion (about 1 000 IU/h) to maintain the APTT or ACT at 1.5 2.0 times of control for 7 days and group LMWH: 0.6ml of low molecular weight heparin (fraxaparin, 0.4 ml if the body weight was less than 60 kg), twice daily subcutaneously for 7 days. The primary end points were myocardial infarction, cardiac or noncardiac death and urgent revascularization 30 days after randomization. The patients enrolled should stay in hospital for at least 7 days. And then,all the patients were followed up for 30 days after admitted to the hospital. Four hundred and two eligible patients were included. The baseline clinical data were comparable between the two groups. Results By 7 days, the incidence of angina pectoris was not significant between the two groups, but more patients needed oral nitroglycerin for pain relief in group SH. Death rate showed insignificant decrease in group LMWH. Composite events were reduced significantly in group LMWH than in group SH. Mild bleeding was more common in group SH patients. By 30 day follow up, both death and composite end point (death, myocardial infarction and urgent revascularization) were significantly reduced in patients receiving LMWH. Conclusion Subcutaneous LMWH is at least as efficacious as continuous intravenous SH for the suppression of heart attacks in the early and late phase of acute coronary syndrome. LMWH is more effective in reducing death and composite cardiovascular events 30 days after drug initiation. Monitoring is not necessary in the routine use of LMWH, which shows more convenience and ease of use." @default.
- W2364490023 created "2016-06-24" @default.
- W2364490023 creator A5038526722 @default.
- W2364490023 date "2000-01-01" @default.
- W2364490023 modified "2023-09-28" @default.
- W2364490023 title "Studies on different anticoagulant therapy in acute coronary syndrome" @default.
- W2364490023 hasPublicationYear "2000" @default.
- W2364490023 type Work @default.
- W2364490023 sameAs 2364490023 @default.
- W2364490023 citedByCount "0" @default.
- W2364490023 crossrefType "journal-article" @default.
- W2364490023 hasAuthorship W2364490023A5038526722 @default.
- W2364490023 hasConcept C126322002 @default.
- W2364490023 hasConcept C141071460 @default.
- W2364490023 hasConcept C168563851 @default.
- W2364490023 hasConcept C204243189 @default.
- W2364490023 hasConcept C2776884760 @default.
- W2364490023 hasConcept C2777557582 @default.
- W2364490023 hasConcept C2777785093 @default.
- W2364490023 hasConcept C2778425758 @default.
- W2364490023 hasConcept C2778704086 @default.
- W2364490023 hasConcept C42219234 @default.
- W2364490023 hasConcept C43376680 @default.
- W2364490023 hasConcept C500558357 @default.
- W2364490023 hasConcept C71924100 @default.
- W2364490023 hasConceptScore W2364490023C126322002 @default.
- W2364490023 hasConceptScore W2364490023C141071460 @default.
- W2364490023 hasConceptScore W2364490023C168563851 @default.
- W2364490023 hasConceptScore W2364490023C204243189 @default.
- W2364490023 hasConceptScore W2364490023C2776884760 @default.
- W2364490023 hasConceptScore W2364490023C2777557582 @default.
- W2364490023 hasConceptScore W2364490023C2777785093 @default.
- W2364490023 hasConceptScore W2364490023C2778425758 @default.
- W2364490023 hasConceptScore W2364490023C2778704086 @default.
- W2364490023 hasConceptScore W2364490023C42219234 @default.
- W2364490023 hasConceptScore W2364490023C43376680 @default.
- W2364490023 hasConceptScore W2364490023C500558357 @default.
- W2364490023 hasConceptScore W2364490023C71924100 @default.
- W2364490023 hasLocation W23644900231 @default.
- W2364490023 hasOpenAccess W2364490023 @default.
- W2364490023 hasPrimaryLocation W23644900231 @default.
- W2364490023 hasRelatedWork W153955259 @default.
- W2364490023 hasRelatedWork W2096740805 @default.
- W2364490023 hasRelatedWork W2149599987 @default.
- W2364490023 hasRelatedWork W2168084825 @default.
- W2364490023 hasRelatedWork W2225236003 @default.
- W2364490023 hasRelatedWork W2357905283 @default.
- W2364490023 hasRelatedWork W2359274850 @default.
- W2364490023 hasRelatedWork W2372378633 @default.
- W2364490023 hasRelatedWork W2373173997 @default.
- W2364490023 hasRelatedWork W2377341313 @default.
- W2364490023 hasRelatedWork W2377557861 @default.
- W2364490023 hasRelatedWork W2385582755 @default.
- W2364490023 hasRelatedWork W2386415536 @default.
- W2364490023 hasRelatedWork W2391358745 @default.
- W2364490023 hasRelatedWork W2393644946 @default.
- W2364490023 hasRelatedWork W2398973969 @default.
- W2364490023 hasRelatedWork W2417331850 @default.
- W2364490023 hasRelatedWork W3030937340 @default.
- W2364490023 hasRelatedWork W3031133563 @default.
- W2364490023 hasRelatedWork W89566418 @default.
- W2364490023 isParatext "false" @default.
- W2364490023 isRetracted "false" @default.
- W2364490023 magId "2364490023" @default.
- W2364490023 workType "article" @default.